If you want to find good companies at bargain prices that will provide you with long-term returns and dividends in any investing climate, then my Seeking Alpha Marketplace service (Good Stocks@Bargain Prices) is a good match for you.Grant Gigliotti is the founder of Beat The Market Analyzer, a leading value investing stock software and has been an active investor for 20+ years. He focuses on the value investing strategies of Warren Buffett to find good companies at bargain prices. He aims to show you how he ...

[UPDATE] BEAT Trading will remain available until 21 July, after which it will be suspended.For more details 👉 https://t.co/yqsRiRjIiqCrypto.com (@cryptocom):🚨 Crypto․com is supporting the $BEAT chain migration 🚨✅ Deposits and withdrawals of BEAT remain available until May 12✅ BEAT in the App and Exchange will be migrated from Polygon to Solana network at a 1:1 ratio✅ BEAT trading remains available during migrationFull https://t.co/oeouTR1IMP ...

智能设备生态系统大致可分为两类：一类是 封闭生态 ，如 苹果 的iOS系列和华为的 HarmonyOS Next；另一类是 开放生态 ， 如基于安卓 的系统。在竞争激烈的智能手机市场中，安卓厂商正努力在高端市场中取得突破，吸引来自 苹果 的用户。为了触达这些高价值、深度绑定于封闭生态的用户，安卓厂商持续探索提升兼容性的方法，试图在 苹果 构建的"围墙花园"中建立连接的通道。 2025年6月25日，vivo正式发布其最新一代折叠屏手机——vivo X Fold 5。除了在重量、厚度持续减轻以及影像能力 进一步提升之外，该产品实现了与 Apple w atch和AirPods的无缝连接，打破了安卓阵营与苹果生态间的壁垒，成为 智能手机行业前所未有的跨生态创新突破。这一举措不仅体现了vivo在生态建设与高端产品方面的差异化战略方向，也为行业在突 破生态壁垒、构建竞争性生态优势方面提供了全新思路。 探索打破生态壁垒的路径 在硬件层面，折叠屏的先发优势以及"移动办公"等小众却粘性极强的使用场景，为厂商提供了新的市场机会，有助于 提升品牌定位并吸引 苹果 用户。然而，仅靠差异化的硬件形态和功能，并不足以说服深度依赖 苹果 ...

Company News - Tesla related news will be broadcast every Friday at 8am PST [1] Personnel - The broadcast will feature @sjvtesla, @futureaza, @Scobleizer, and @_SFTahoe [1]

Group 1 - The core focus of Quad 7 Capital is to provide investment opportunities through their BAD BEAT Investing platform, emphasizing both long and short trades with a proven track record of success [1] - Quad 7 Capital has maintained an average position of 95% long and 5% short since May 2020, showcasing their strategic approach to market conditions [1] - The team consists of 7 analysts with diverse expertise in business, policy, economics, mathematics, game theory, and sciences, enhancing their research capabilities [1] Group 2 - BAD BEAT Investing offers benefits such as understanding market dynamics, executing well-researched trade ideas weekly, and access to multiple chat rooms for collaboration [2] - Members receive daily summaries of key analyst upgrades and downgrades, which aids in informed decision-making [2] - The platform also provides education on basic options trading and extensive trading tools to enhance investor proficiency [2]

Core Viewpoint - IGI Therapeutics and AbbVie have entered into an exclusive licensing agreement for ISB 2001, a novel trispecific T-cell engager targeting multiple myeloma, which is currently in Phase 1 clinical trials [1][2]. Company Overview - IGI Therapeutics is a clinical-stage biotechnology company focused on developing innovative biologics in oncology, utilizing its proprietary BEAT® technology platform to create first-in-class multispecific therapies [7]. - AbbVie is a global biopharmaceutical company dedicated to discovering and delivering innovative medicines across various therapeutic areas, including oncology [8]. Product Details - ISB 2001 is designed to target BCMA and CD38 on myeloma cells and CD3 on T cells, aiming to improve safety and efficacy compared to first-generation bispecific antibodies [3]. - The drug has shown a sustained overall response rate (ORR) of 79% and a complete/stringent complete response (CR/sCR) rate of 30% in a heavily pretreated patient population [3]. Licensing Agreement - Under the agreement, AbbVie will have exclusive rights to develop, manufacture, and commercialize ISB 2001 in North America, Europe, Japan, and Greater China [2]. - IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in milestone payments, along with tiered, double-digit royalties on net sales [2]. Regulatory Designations - ISB 2001 received Orphan Drug Designation from the U.S. FDA in July 2023 and Fast Track Designation for treating relapsed/refractory myeloma patients in May 2025 [4]. BEAT® Platform - The BEAT® platform enables the development of next-generation immune cell engagers with enhanced stability and function, addressing limitations of traditional bispecific antibody production [5]. - Key features include multispecific versatility, optimized engineering for precise modulation, and robust manufacturability [5].

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)NORTH CHICAGO, Ill. and NEW YORK, July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases."Multispecifics ...

大公司： 消息称星巴克中国竞购估值或达100亿美元，近30家机构参与角逐 据三位知情人士透露，星巴克中国业务潜在股权出售已吸引多份报价，对该咖啡连锁品牌的估值最高达 100亿美元。知情人士称，近30家国内外私募股权机构已提交非约束性报价，竞标估值区间为50亿至100 亿美元，最终交易价可能接近区间上限。其中一位人士指出，星巴克当前市值约1080亿美元，中国业务 贡献超8%全球营收，合理估值应在90亿美元左右。（新浪财经） 高德地图上线AR打卡功能 阿里巴巴集团旗下高德地图正式推出AR打卡功能，通过AI技术与地图服务的深度融合，打造虚实结合 的沉浸式打卡体验，推动地图导航服务向世界探索与生活记录领域进阶。用户只需打开并登录高德地图 App，点击页面右上角的"+"号，即可找到打卡入口，一键开启AR打卡之旅。目前，高德地图AR打卡功 能已面向所有用户全量开放，用户将App更新至最新版即可体验。 越疆科技已申请多项机器人相关专利 36氪获悉，7月9日，越疆科技正式发布六足仿生机器狗。越疆六足机器狗补全了公司"机械臂+人形+六 足"的具身机器人平台建设规划，锚定石油平台防爆巡检、光伏电站智能运维、地震废墟搜救等垂直场 ...

2025年7月8日 ， 瑞士医疗科技公司 Aktiia 宣布，其 G0无袖带血压监测系统 获得美国食品药品监督管理局（FDA）510(k)批准。 这是全球首款被批准可作为非处方 （OTC）产品上市的无袖带血压监测可穿戴设备，标志着血压管理从传统袖带向无创、连续、可穿戴技术的转折点。 G0系统计划于 2026年 在美国上市，初期将通过零售药店、电商和医疗渠道销售，预计售价在300美元左右。此前，该系统已 获得CE认证，并 在欧洲多个国家以 Hilo品牌销售。 # 无袖带血压监 测的 核心突破 Aktiia G0系统（美国市场称为Hilo Band），核心技术基于 光体积描记法（PPG） ，通过佩戴在手腕上的光学传感器，捕捉血管随心跳产生的微小体积变化，结合自 研的 CALFREE算法 ，实时估算收缩压（SBP）与舒张压（DBP）。 传统的血压监测依赖充气袖带，虽然精准，但存在几个痛点：测量过程需要主动操作，患者往往难以坚持；袖带反复充气造成不适，特别是夜间监测干扰睡眠；测 量频率低，可能漏掉血压波动。 G0系统针对这些问题，做出了以下技术突破： 虽然精度略低于传统袖带设备，但在连续性和用户体验方面，G0系统实现 ...

Every vector database out there is both faster and slower than any other competitor — if you believe all the benchmarketing out there. Let's turn the marketing into useful benchmarks that actually help you: 1. How not to benchmark (spoiler: don’t trust the glossy charts). 2. What’s uniquely tricky about benchmarking vector search. 3. How to build meaningful benchmarks tailored to your use case. PS: Yes, you will have to get your hands dirty. Never believe a benchmark that you haven't tweaked yourself. About ...